Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Avandia REMS’ Elements To Assure Safe Use

You may also be interested in...



Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says

FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.

Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says

FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.

Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety

The Risk Evaluation and Mitigation Strategy for GlaxoSmithKline’s Avandia (rosiglitazone) includes a prominent role for Takeda’s competing thiazolidinedione Actos (pioglitazone).

Related Content

Topics

UsernamePublicRestriction

Register

PS053430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel